Mayo Clinic researchers have discovered a potential explanation for why immunotherapy often fails to help patients with metastatic colorectal cancer. In a study published in Clinical Cancer Research, the team identified two specific proteins—fibronectin and smooth muscle actin—in colorectal cancer tissue that are associated with resistance to immunotherapy treatments. This finding addresses a critical gap in understanding why many patients do not respond to this advanced cancer treatment.
The Need for Predictive Biomarkers
Immunotherapy represents a major advancement in cancer treatment, yet many patients including those with metastatic colorectal cancer show no response. Dr. Frank Sinicrope, senior author of the study, emphasized the importance of developing predictive biomarkers to guide patient selection. Identifying treatment-resistant patients early can prevent unnecessary exposure to therapies that may prove ineffective and cause significant side effects, ultimately improving patient care and outcomes.
Innovative Research Methodology
The research team employed digital spatial analysis, an advanced technique that simultaneously examines the expression and spatial relationships of multiple proteins within tissue. This approach provided a comprehensive view of the tumor microenvironment, revealing how proteins inside and around tumor cells interact. Dr. Sinicrope compared this method to obtaining an aerial view of a neighborhood, allowing researchers to observe complex cellular relationships and interactions within the cancer ecosystem.
Key Findings and Protein Identification
The study focused on ten regions at the tumor’s invasive front, where cancer cells advance and the immune system attempts to combat the cancer. Analysis of 71 different proteins revealed that fibronectin and smooth muscle actin, located in the tumor’s epithelial regions, correlated strongly with immunotherapy resistance and shorter time to disease progression. These extracellular matrix proteins were found to be produced by cancer-associated fibroblasts within the tumor microenvironment.
Clinical Implications and Future Directions
Further investigation demonstrated that these proteins contribute to suppressing antitumor immune responses. This discovery provides crucial insights into the mechanisms of treatment resistance and opens new possibilities for improving patient selection for immunotherapy. The research may lead to strategies for overcoming resistance and developing more effective treatment approaches for metastatic colorectal cancer patients who currently have limited therapeutic options.
Related topics
